Search results
Results from the WOW.Com Content Network
Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected.
The FDA's decision is a win for Lilly, the drug's manufacturer, according to the Associated Press, prices and ways to access drugs like Zepbound and Mounjaro could be affected as a result of the move.
On Dec. 11, the company announced a strategic partnership with direct-to-consumer healthcare application, Ro. Per the announcement, Ro will act as an additional channel for Lilly in order to ...
A news release from Eli Lilly in June 2024 outlines some concerns surrounding compounded versions of tirzepatide (the active ingredient in Mounjaro and Zepbound), some of which contained bacteria ...
(Reuters) - Four doses of Eli Lilly's diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's website showed.
Lilly's Mounjaro has been on the U.S. FDA's shortage list since late 2022, while Zepbound was added to the list in April this year. US FDA says all doses of Lilly's weight-loss and diabetes drug ...
Eli Lilly recently announced plans to sell cheaper, single-dose vials of Zepbound. Fitch noted that many patients are often unaware that their insurance will cover GLP-1 medications.
Eli Lilly has many other medicines helping drive top-line growth and several exciting pipeline candidates. The company's revenue and earnings should grow at a rate much higher than the average ...